BioNTech SE (BNTX) Current Deferred Revenue (2018 - 2025)

BioNTech SE (BNTX) has 8 years of Current Deferred Revenue data on file, last reported at $878.7 million in Q4 2025.

• In Q4 2025, Current Deferred Revenue rose 178.85% year-over-year to $878.7 million; the TTM figure through Dec 2025 stood at $878.7 million (up 178.85% YoY), while the FY2025 annual figure was $852.9 million, up 170.65% from the prior year.
• Current Deferred Revenue eased to $878.7 million in Q4 2025, from $930.7 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $1.1 billion in Q2 2025 and bottomed at $48.9 million in Q1 2023.
• A 5-year average of $454.6 million and a median of $384.0 million in 2021 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2023 — Current Deferred Revenue sank 77.29% — and 2024, when it soared 741.67%.
• Year by year, Current Deferred Revenue stood at $212.9 million in 2021, then plunged by 63.05% to $78.7 million in 2022, then jumped by 445.08% to $428.8 million in 2023, then declined by 26.5% to $315.1 million in 2024, then surged by 178.85% to $878.7 million in 2025.
• The last three Current Deferred Revenue figures came in at $878.7 million (Q4 2025), $930.7 million (Q3 2025), and $1.1 billion (Q2 2025), per Business Quant data.

Peer Comparison